Type 2 diabetes mellitus is a progressive disease that is characterized by the appearance of
insulin resistance. The term insulin resistance is very wide and could affect different proteins …

TOR (target of rapamycin) and its mammalian ortholog mTOR have been discovered in an
effort to understand the mechanisms of action of the immunosuppressant drug rapamycin …

Tau protein accumulation is the most common pathology among degenerative brain
diseases, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP) …

There are currently no disease-modifying therapies for the treatment of tauopathies, a group
of progressive neurodegenerative disorders that are pathologically defined by the presence …

The aim of this review is to critically analyze promises and limitations of pharmacological
inducers of autophagy against protein misfolding-associated neurodegeneration. Effective …

Elevated mammalian target of rapamycin (mTOR) signaling has been found in Alzheimer's
disease (AD) patients and is linked to diabetes and aging, two known risk factors for AD …

Mechanistic/mammalian target of rapamycin (mTOR) belongs to the phosphatidylinositol
kinase-related kinase (PIKK) family. mTOR signaling is required for the commencement of …

All people want to age “successfully,” maintaining functional capacity and quality of life as
they reach advanced age. Achieving this goal depends on preserving optimal cognitive and …

In recent decades, traditional eating habits have been replaced by a more globalized diet,
rich in saturated fatty acids and simple sugars. Extensive evidence shows that these dietary …

Tau pathology was recently identified as a key driver of disease progression and an
attractive therapeutic target in Alzheimer's disease (AD). Selenomethionine (Se-Met), a …